Glycanostics
- Biotech or pharma, therapeutic R&D
- Diagnostics
- Synthesis, analytic, diagnostic services
- Medical device or technology
Glycanostics® is developing early-stage, highly accurate and unique cancer diagnostic tests that analyse changes in glycan structures in glycoprotein biomarkers from blood serum.
Key facts:
- In October 2024 we became members of the highly prestigious EIC Scaling Club that unites 120 European deep-tech scale-ups with unicorn potential
- Our aim is to develop highly accurate, early-stage tests for the detection of 11 types of cancer based on analysis of glycans in blood serum
- Our patented technology enables to analyse glycans using Magnetic-based-ELISA
- Our solution represents a novel and unique approach, suitable for massive testing in laboratory chains, it detects cancer in early stage, with accuracy exceeding competitors, it is highly affordable and organ specific
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}